語系:
繁體中文
English
日文
簡体中文
說明(常見問題)
登入
回首頁
切換:
標籤
|
MARC模式
|
ISBD
Managing metastatic prostate cancer ...
~
Balaji, K.C.
Managing metastatic prostate cancer in your urological oncology practice[electronic resource] /
紀錄類型:
書目-語言資料,印刷品 : Monograph/item
杜威分類號:
616.99463075
書名/作者:
Managing metastatic prostate cancer in your urological oncology practice/ edited by K.C. Balaji.
其他作者:
Balaji, K.C.
出版者:
Cham : : Springer International Publishing :, 2016.
面頁冊數:
xiii, 280 p. : : ill. (some col.), digital ;; 24 cm.
Contained By:
Springer eBooks
標題:
Prostate - Cancer
標題:
Medicine & Public Health.
標題:
Urology.
標題:
Oncology.
ISBN:
9783319313412
ISBN:
9783319313399
內容註:
Introduction -- Pathophysiology of Castration-Resistant Prostate Cancer -- Androgen Receptor Signaling in Castration Resistant Prostate Cancer -- Non-Androgen Signaling Pathways in Castration-Resistant Prostate Cancer -- Predictive Models in Castration Resistant Prostate Cancer -- Docetaxel in Advanced and Castration Resistant Prostate Cancer -- Combination Treatment Strategies with Docetaxel in Patients with Metastatic Prostate -- Cancer Vaccines in Castration Resistant Prostate Cancer – An evolution in design -- Abiraterone for the treatment of mCRPC -- Enzalutamide in Metastatic Castration Resistant Prostate Cancer -- Radium-223 in Metastatic Castrate Resistant Prostate Cancer -- Cabazitaxel for the Treatment of Prostate Cancer -- Sequencing Therapies in Metastatic Castration Resistant Prostate Cancer -- Bone Preservation Strategies for Men on Androgen Deprivation Therapy -- Novel Therapies in Castration-Resistant Prostate Cancer.
摘要、提要註:
This text provides a comprehensive review of pathophysiology, molecular and cell biology aspects of CRPC, discusses all major clinical trials that have led to approval of 6 new drugs since 2004, explores the role of bone preservation strategies, in depth analysis of combination and sequencing strategies, outlines upcoming novel drugs and trends in research, and stresses the role of palliative care in this incurable disease. Managing Metastatic Prostate Cancer in Your Urological Oncology Practice will serve as a very useful resource for physicians and researchers dealing with, and interested in prostate cancer. It provides a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts. All chapters are written by experts in their fields and will include the most up to date scientific and clinical information.
電子資源:
http://dx.doi.org/10.1007/978-3-319-31341-2
Managing metastatic prostate cancer in your urological oncology practice[electronic resource] /
Managing metastatic prostate cancer in your urological oncology practice
[electronic resource] /edited by K.C. Balaji. - Cham :Springer International Publishing :2016. - xiii, 280 p. :ill. (some col.), digital ;24 cm.
Introduction -- Pathophysiology of Castration-Resistant Prostate Cancer -- Androgen Receptor Signaling in Castration Resistant Prostate Cancer -- Non-Androgen Signaling Pathways in Castration-Resistant Prostate Cancer -- Predictive Models in Castration Resistant Prostate Cancer -- Docetaxel in Advanced and Castration Resistant Prostate Cancer -- Combination Treatment Strategies with Docetaxel in Patients with Metastatic Prostate -- Cancer Vaccines in Castration Resistant Prostate Cancer – An evolution in design -- Abiraterone for the treatment of mCRPC -- Enzalutamide in Metastatic Castration Resistant Prostate Cancer -- Radium-223 in Metastatic Castrate Resistant Prostate Cancer -- Cabazitaxel for the Treatment of Prostate Cancer -- Sequencing Therapies in Metastatic Castration Resistant Prostate Cancer -- Bone Preservation Strategies for Men on Androgen Deprivation Therapy -- Novel Therapies in Castration-Resistant Prostate Cancer.
This text provides a comprehensive review of pathophysiology, molecular and cell biology aspects of CRPC, discusses all major clinical trials that have led to approval of 6 new drugs since 2004, explores the role of bone preservation strategies, in depth analysis of combination and sequencing strategies, outlines upcoming novel drugs and trends in research, and stresses the role of palliative care in this incurable disease. Managing Metastatic Prostate Cancer in Your Urological Oncology Practice will serve as a very useful resource for physicians and researchers dealing with, and interested in prostate cancer. It provides a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts. All chapters are written by experts in their fields and will include the most up to date scientific and clinical information.
ISBN: 9783319313412
Standard No.: 10.1007/978-3-319-31341-2doiSubjects--Topical Terms:
447892
Prostate
--Cancer
LC Class. No.: RC280.P7
Dewey Class. No.: 616.99463075
Managing metastatic prostate cancer in your urological oncology practice[electronic resource] /
LDR
:02811nam a2200313 a 4500
001
447491
003
DE-He213
005
20160930102024.0
006
m d
007
cr nn 008maaau
008
161201s2016 gw s 0 eng d
020
$a
9783319313412
$q
(electronic bk.)
020
$a
9783319313399
$q
(paper)
024
7
$a
10.1007/978-3-319-31341-2
$2
doi
035
$a
978-3-319-31341-2
040
$a
GP
$c
GP
041
0
$a
eng
050
4
$a
RC280.P7
072
7
$a
MJS
$2
bicssc
072
7
$a
MED088000
$2
bisacsh
082
0 4
$a
616.99463075
$2
23
090
$a
RC280.P7
$b
M266 2016
245
0 0
$a
Managing metastatic prostate cancer in your urological oncology practice
$h
[electronic resource] /
$c
edited by K.C. Balaji.
260
$a
Cham :
$b
Springer International Publishing :
$b
Imprint: Springer,
$c
2016.
300
$a
xiii, 280 p. :
$b
ill. (some col.), digital ;
$c
24 cm.
505
0
$a
Introduction -- Pathophysiology of Castration-Resistant Prostate Cancer -- Androgen Receptor Signaling in Castration Resistant Prostate Cancer -- Non-Androgen Signaling Pathways in Castration-Resistant Prostate Cancer -- Predictive Models in Castration Resistant Prostate Cancer -- Docetaxel in Advanced and Castration Resistant Prostate Cancer -- Combination Treatment Strategies with Docetaxel in Patients with Metastatic Prostate -- Cancer Vaccines in Castration Resistant Prostate Cancer – An evolution in design -- Abiraterone for the treatment of mCRPC -- Enzalutamide in Metastatic Castration Resistant Prostate Cancer -- Radium-223 in Metastatic Castrate Resistant Prostate Cancer -- Cabazitaxel for the Treatment of Prostate Cancer -- Sequencing Therapies in Metastatic Castration Resistant Prostate Cancer -- Bone Preservation Strategies for Men on Androgen Deprivation Therapy -- Novel Therapies in Castration-Resistant Prostate Cancer.
520
$a
This text provides a comprehensive review of pathophysiology, molecular and cell biology aspects of CRPC, discusses all major clinical trials that have led to approval of 6 new drugs since 2004, explores the role of bone preservation strategies, in depth analysis of combination and sequencing strategies, outlines upcoming novel drugs and trends in research, and stresses the role of palliative care in this incurable disease. Managing Metastatic Prostate Cancer in Your Urological Oncology Practice will serve as a very useful resource for physicians and researchers dealing with, and interested in prostate cancer. It provides a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts. All chapters are written by experts in their fields and will include the most up to date scientific and clinical information.
650
0
$a
Prostate
$x
Cancer
$x
Treatment.
$3
447892
650
1 4
$a
Medicine & Public Health.
$3
463493
650
2 4
$a
Urology.
$3
403368
650
2 4
$a
Oncology.
$3
205017
700
1
$a
Balaji, K.C.
$3
641277
710
2
$a
SpringerLink (Online service)
$3
463450
773
0
$t
Springer eBooks
856
4 0
$u
http://dx.doi.org/10.1007/978-3-319-31341-2
950
$a
Medicine (Springer-11650)
筆 0 讀者評論
多媒體
多媒體檔案
http://dx.doi.org/10.1007/978-3-319-31341-2
評論
新增評論
分享你的心得
Export
取書館別
處理中
...
變更密碼
登入